PRF Technologies Ltd. (NasdaqCM: PRFX)
Health Care · Pharmaceuticals · IL
$0.99
-0.23% today · -88.5% 1Y
PRF Technologies Ltd. (NasdaqCM: PRFX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $3.03M and employs 7 people.
Over the last twelve months the share price has lost 88.5%, trading between 0.91 and 9.60.
Tweenvest scores PRF Technologies Ltd. across four factors: quality 26/100, value 60/100. Its strongest factor is value.
PRFX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.03M
- Revenue (TTM)
- $17.00K
- P/E
- —
- EPS
- -7.47
- Dividend yield
- —
- Beta (5Y)
- 1.04
- 52-week high
- $9.60
- 52-week low
- $0.91
- Avg volume (3M)
- —
- Shares outstanding
- 3.04M
- Employees
- 7
- Next earnings
- —
About PRF Technologies Ltd.
PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.
- ISIN
- IL0011651580
- Founded
- 2007
- Listed since
- Sep 1, 2020
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.